1. Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer
   Jeyshka M. Reyes-González et al, 2020, Cancers CrossRef
2. Biomaterial considerations for ovarian cancer models
   Maranda Kramer et al, 2023, Frontiers in Materials CrossRef
3. CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies
   Iris Lodewijk et al, 2023, Frontiers in Immunology CrossRef
4. Wnt Signaling in Ovarian Cancer Stemness, EMT, and Therapy Resistance
   null Teeuwssen et al, 2019, Journal of Clinical Medicine CrossRef